• Home
  • Opportunities
  • PhD Opportunity: Integrative genomics and immunobiology in Hairy cell leukaemia
Back to all opportunities
  • Study
  • VCCC Alliance
  • Royal Melbourne Hospital
13 Sep 2022

PhD Opportunity: Integrative genomics and immunobiology in Hairy cell leukaemia

The research team at Royal Melbourne Hospital's ACRF Translational Research Laboratory have a research opportunity for a PhD student to investigate the genomics and immunobiology in Hairy Cell Leukaemia.

What is Hairy cell leukaemia?

Hairy cell leukaemia (HCL) is a rare and slowly growing cancer of B lymphocytes. It has unique features and is often defined by the presence of a specific genetic change known as the BRAF V600E mutation. In some rare cases BRAF V600E mutations are not present and different genetic causes have been identified including our recently reported novel observation of an alternative type of BRAF alteration.

For those patients with HCL, that do not contain the BRAF V600E mutation, there is a need to understand the precise genomic drivers of these atypical cases as those discoveries may critically inform personalized targeted treatment strategies.

Patients with HCL are commonly treated with cladribine (chemotherapy) and rituximab (an antibody targeting B cells) and often achieve complete and durable remission, however as many as 50% of patients experience disease relapse, requiring further treatment. Why some patients require recurrent therapy and others have long term remissions is unknown.

We believe that understanding the genetics of the hairy cells and how the immune system responds to them may help answer this question. Our initial findings in the analysis of bone marrow samples taken before and after cladribine treatment has shown that patients with durable remissions have greater rates of immune recovery indicating that treatments that enhance immune recovery may allow long term remissions to be achieved. New molecularly-targeted therapies such as BRAF, MEK and BTK inhibitors provide non-chemotherapy options in HCL. The genomic mechanisms of resistance and the immune impact of these novel agents in HCL are largely unknown and may be of value for guiding subsequent therapy decisions.

About the project

This research project is available to science graduates seeking to undertake a PhD to join the ACRF as part of their thesis with scholarship funding available.

The ideal candidate will help achieve our aims to further define the genomic and immune landscape of HCL as it relates to diagnosis, therapeutic decisions and disease monitoring in patients. Through this study we will develop and consolidate new discoveries via state-of-the-art genomic profiling and cutting edge immune profiling to help inform personalized treatment and optimize health outcomes.

Supervisors

  • Prof David Ritchie, Deputy Director, Clinical Haematologist and BMT physician
  • A/Prof Rachel Koldej, Senior Scientist, ACRF Translational Research Laboratory

Is this thesis right for you?

Contact Rachel Koldej for more information or submit your expression of interest by emailing you CV to: [email protected]

Get the latest in cancer news, events and more, direct to your inbox
Join a network of Victorian cancer researchers, clinicians and consumers to keep your finger on the pulse.